15038 studies
Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as nonalcoholic fatty liver disease (NAFLD), has become a significant public health issue worldwide, with a pronounced impact in India due to the escalating rates of obe…
BACKGROUND: Sodium-glucose transporter 2 inhibitors (SGLT-2Is) and Semaglutide may increase the risk of sarcopenia and bone fragility in vulnerable populations, yet their effects on body composition in patients with type 2 diabetes mellitus (T2DM) an…
This systematic review evaluates the long-term efficacy and safety of GLP-1 receptor agonists in the management of obesity, focusing on data from high-quality randomized controlled trials published between 2018 and 2025. This review synthesizes findi…
BACKGROUND: Obesity affects >890 million adults worldwide, and traditional lifestyle interventions often lack long-term success. While glucagonlike peptide-1 receptor agonists (GLP-1RAs) have shown strong weight loss outcomes, access to specialist ca…
BACKGROUND: GLP-1 receptor agonists (GLP-1 RA) reduce major adverse cardiovascular events in patients with diabetes mellitus and atherosclerotic cardiovascular disease (ASCVD) or increased cardiovascular risk. Recently, the GLP-1 RA semaglutide was r…
AIMS: This post hoc analysis investigates the impact of baseline characteristics on the efficacy and safety of oral semaglutide in a Chinese population with type 2 diabetes. MATERIALS AND METHODS: Chinese participants from the PIONEER 11 and 12 trial…
OBJECTIVE: Glucagon-like peptide-1 (GLP-1) reduces systemic and gut inflammation. Here we assessed whether gain or loss of GLP-1 receptor (GLP-1R) signaling modifies the extent of gut injury and inflammation in experimental murine acute graft vs. hos…
Obesity management is evolving with the integration of digital and pharmacological innovations. Continuous Glucose Monitoring (CGM) offers dynamic insights into glucose variability, while glucagon-like peptide-1 receptor agonists (GLP-1 RAs), such as…
Oral bioavailability of peptides can be improved by targeting specific gastro-intestinal segments, such as the ileum. However, oral drug products with a drug release in the ileum are challenging to develop. The main objectives of this study were: (a)…
Newer developments in endocrine pharmacology have blurred the distinction between biosimilars and generics. The originator semaglutide, for example, is a biologically active compound, but later versions are chemically synthesized generics. Tirzepatid…
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) were approved by the FDA to treat type 2 diabetes (T2D) and to reduce the risk of major cardiovascular events in patients with T2D and known heart disease. With an alarming rise in T2D prevalence…
Innovations in liquid chromatography stationary phase media can address emerging peptide separation and purification challenges. Herein, we report the synthesis of novel carbon microbeads from natural micrographite flakes as the starting material (re…
Lophine, the first chemiluminescent compound discovered in history, has rarely been applied for in vivo imaging since its discovery in 1877. In this report, we demonstrate that lophine's chemiluminescence emission could be significantly enhanced by c…
Substance use disorders (SUDs) remain a major public health challenge, with existing pharmacotherapies offering limited long-term efficacy. Traditional treatments focus on dopaminergic systems but often overlook the complex interplay between metaboli…
: Ischemic optic neuropathies (IONs) are significant causes of vision loss resulting from compromised blood flow to the optic nerve. Diabetes mellitus (DM) exacerbates the risk of IONs through chronic hyperglycemia and associated vascular dysfunction…
BACKGROUND: In May 2019, the US Food and Drug Administration (FDA) initiated Project Orbis with the aim of providing patients faster access to promising cancer treatments by promoting coordination with international regulatory agencies, including Hea…